Journal of hepato-biliary-pancreatic sciences · 2025
Prognostic Impact of HER2 Overexpression in Intraductal Papillary Neoplasm of the Bile Duct.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Onoe Shunsuke, Mizuno Takashi, Watanabe Nobuyuki, Kawakatsu Shoji, Yamaguchi Junpei, Baba Taisuke, Yamamoto Ryusei, Shimoyama Yoshie, Kokuryo Toshio, Ebata Tomoki
Аннотация
BACKGROUND: Overexpression of human epidermal growth factor receptor 2 (HER2) is a recognized prognostic marker and therapeutic target in oncology. However, its clinical significance in intraductal papillary neoplasm of the bile duct (IPNB) remains unclear.
METHODS: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi-quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2-negative and HER2-positive groups, respectively.
RESULTS: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2-positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2-positive group. The HER2-positive group demonstrated significantly worse overall survival than the HER2-negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.
CONCLUSION: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.
METHODS: This retrospective study reviewed patients who underwent resection for IPNB between 1998 and 2011. HER2 overexpression was evaluated by immunohistochemistry and semi-quantitatively categorized into four grades (score 0, 1+, 2+, 3+); the former two and the latter two grades defined HER2-negative and HER2-positive groups, respectively.
RESULTS: A total of 184 IPNB cases were analyzed, of which 12 patients (6.5%) were diagnosed with HER2-positive disease. There were no significant differences between the groups in clinicopathologic characteristics such as tumor location, histologic type, or invasion depth, with the exception of superficial extension, which was significantly more frequent in the HER2-positive group. The HER2-positive group demonstrated significantly worse overall survival than the HER2-negative group (25% vs. 49% at 5 years, p = 0.030). In multivariable analysis, HER2 positivity, age ≥ 70, percutaneous transhepatic biliary drainage, nodal metastasis, and positive margin status were identified as independent prognostic factors.
CONCLUSION: HER2 overexpression is an independent biologic marker for unfavorable survival, though infrequent in IPNB.